The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.
You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.
We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.
We are interested in where in or outside the cell the gene product carries out its function.
We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.
Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.
The human CLCN7 gene (UniProt accession P51798) encodes ClC-7, a lysosomal chloride/proton antiporter belonging to the CLC (chloride channel) family of proteins (zifarelli2022theroleof pages 1-2, bose2021neurodegenerationupondysfunction pages 1-2). ClC-7 is ubiquitously expressed with particularly high levels in the central and peripheral nervous system, where it colocalizes with LAMP-1, a marker for late endosomes and lysosomes (zifarelli2022theroleof pages 1-2). The protein shares the general structural architecture common to CLC family members, comprising a transmembrane domain with an hourglass-shaped ion permeation pathway and a large cytoplasmic C-terminus containing two CBS (cystathionine β synthase) domains (zifarelli2022theroleof pages 1-2, zifarelli2022theroleof pages 2-4).
ClC-7 functions as a strict 2Cl⁻/H⁺ antiporter, catalyzing the coupled movement of two chloride ions and one proton in opposite directions across lysosomal membranes (bose2021neurodegenerationupondysfunction pages 1-2, zifarelli2022theroleof pages 2-4, schrecker2020cryoemstructureof pages 1-2). In the physiological context of acidic lysosomes, this transport is functionally described as the uptake of two chloride ions into the lysosomal lumen coupled to the efflux of one proton to the cytosol (polovitskaya2024gainoffunctionvariantsin pages 1-2, polovitskaya2024gainoffunctionvariantsin pages 2-4). The electrogenic nature of this 2:1 exchange makes ClC-7 unique among lysosomal ion transporters (schrecker2020cryoemstructureof pages 1-2).
High-resolution cryo-EM structures solved at 2.8 Å resolution have revealed the molecular details of ClC-7's transport mechanism (schrecker2020cryoemstructureof pages 1-2). The ion permeation pathway contains three anion binding sites with a characteristic narrowing at the selectivity filter (zifarelli2022theroleof pages 2-4). Two conserved glutamate residues play critical roles in the transport cycle: the "gating glutamate" (Glu247 in human ClC-7) undergoes conformational changes that couple chloride and proton movement, while the "proton glutamate" (Glu314) likely serves as a proton acceptor site (zifarelli2022theroleof pages 2-4, schrecker2020cryoemstructureof pages 1-2). The chloride and proton pathways diverge at the cytosolic side, with proton transport occurring through a water-filled cavity around Glu314 (zifarelli2022theroleof pages 2-4).
When expressed at the plasma membrane for experimental characterization, ClC-7 exhibits slowly activating currents with strong outward rectification, activating on the timescale of seconds at depolarized voltages (zifarelli2022theroleof pages 2-4, hilton2025mechanismofphosphoinositide pages 1-3). This voltage-dependent activation suggests that ClC-7 must be in an "activated state" for the transport cycle to proceed, similar to voltage-gated ion channels (hilton2025mechanismofphosphoinositide pages 1-3). The molecular basis for this common gating mechanism appears to involve interactions between the transmembrane and cytosolic domains (hilton2025mechanismofphosphoinositide pages 1-3).
ClC-7 localizes primarily to lysosomal membranes in all cell types, where it co-localizes with late endosomal and lysosomal markers such as LAMP-1 (zifarelli2022theroleof pages 1-2, bose2021neurodegenerationupondysfunction pages 2-4). Proper lysosomal targeting requires the protein's N-terminal dileucine motifs and its obligatory association with the β-subunit OSTM1 (zifarelli2022theroleof pages 1-2, schrecker2020cryoemstructureof pages 1-2).
In osteoclasts, ClC-7 exhibits a specialized dual localization: in addition to the typical lysosomal localization, it is also expressed at the ruffled border, a specialized membrane domain facing the bone resorption lacuna (zifarelli2022theroleof pages 1-2, bose2021neurodegenerationupondysfunction pages 2-4). At this site, ClC-7 plays a critical role in acidifying the extracellular resorption lacuna, which is essential for dissolving the hydroxyapatite mineral component of bone during bone remodeling (chen2026spectrumandfunctions pages 2-3, rossler2021efficientgenerationof pages 1-5).
Unlike other mammalian CLC transporters, ClC-7 requires the β-subunit OSTM1 (osteopetrosis-associated transmembrane protein 1) for proper localization, stability, and full activity (zifarelli2022theroleof pages 1-2, bose2021neurodegenerationupondysfunction pages 1-2). Structural studies reveal that OSTM1 binds to the periphery of the ClC-7 dimer via a single transmembrane helix, with its heavily glycosylated N-terminus forming a luminal cap that entirely covers the luminal surface of ClC-7 (schrecker2020cryoemstructureof pages 1-2). This protective covering shields ClC-7 from the degradative environment of the acidic lysosomal lumen (schrecker2020cryoemstructureof pages 1-2). While OSTM1 binding does not induce large-scale rearrangements of ClC-7 structure, it does have minor effects on the conformation of the ion-conduction pathway, potentially contributing to its regulatory role (schrecker2020cryoemstructureof pages 1-2).
ClC-7 is directly inhibited by the lysosomal phosphoinositide lipid PI(3,5)P₂ (phosphatidylinositol 3,5-bisphosphate), which is generated in the cytosolic leaflet of endolysosomal membranes by the kinase PIKFyve (polovitskaya2024gainoffunctionvariantsin pages 1-2, hilton2025mechanismofphosphoinositide pages 1-3). Recent structural and functional studies have elucidated the molecular mechanism of this inhibition: PI(3,5)P₂ binds at the interface between the transmembrane domain and cytosolic C-terminal domains, with its negatively charged headgroup forming an extended electrostatic interface that includes residues from both domains (hilton2025mechanismofphosphoinositide pages 1-3).
Groundbreaking work by Hilton et al. (2025) demonstrated that PI(3,5)P₂ binding dramatically remodels the structure of ClC-7 by inducing close association between cytosolic and transmembrane domains (hilton2025mechanismofphosphoinositide pages 1-3). This binding network includes the tyrosine residue Y715, which is mutated in gain-of-function disease. Conversely, ClC-7 activation correlates with dissociation and increased disorder of the cytoplasmic domain along with novel transmembrane domain conformations, revealing a mechanistic link between specific lysosomal lipids, transporter regulation, and the enigmatic basis of the ClC-7 slow gate (hilton2025mechanismofphosphoinositide pages 1-3).
Depletion of PI(3,5)P₂ results in enlarged, hyperacidified lysosomes, with the hyperacidification primarily mediated by unrestrained ClC-7 activity (hilton2025mechanismofphosphoinositide pages 1-3).
A major advance in understanding ClC-7 function came from recent studies demonstrating that ClC-7 establishes and maintains a substantial lysosomal chloride gradient. Work by Zhang et al. (2023) and Wu/Freeman et al. (2023) showed that ClC-7 creates a roughly 2- to 4-fold concentration gradient of chloride in lysosomes and phagolysosomes (zhang2023lysosomalchloridetransporter pages 1-2, feng2023notjustprotons pages 1-2). This chloride accumulation occurs even when lysosomal acidification is maintained by other mechanisms, indicating that chloride homeostasis is a primary and independent function of ClC-7 (zhang2023lysosomalchloridetransporter pages 1-2, feng2023notjustprotons pages 1-2).
One of the most significant recent discoveries is that lysosomal chloride itself—independent of pH—directly regulates the activity of lysosomal hydrolases. Zhang et al. (2023) demonstrated that ClC-7 maintains luminal chloride levels required for optimal cathepsin B and L activity (zhang2023lysosomalchloridetransporter pages 1-2). Loss of ClC-7 function reduces lysosomal chloride without necessarily abolishing acidification, yet this still causes defective cargo degradation (zhang2023lysosomalchloridetransporter pages 1-2, feng2023notjustprotons pages 1-2). In vitro chloride supplementation experiments showed that chloride ions directly bind to cathepsins and enhance their proteolytic activity (zhang2023lysosomalchloridetransporter pages 1-2). This finding fundamentally shifted the understanding of ClC-7 from a protein that merely supports acidification to one that regulates lysosomal function through chloride-dependent enzyme activation (zhang2023lysosomalchloridetransporter pages 1-2, feng2023notjustprotons pages 1-2).
Proper chloride levels maintained by ClC-7 are essential for preserving lysosomal membrane stability. Studies in C. elegans showed that loss of the ClC-7 ortholog (CLH-6) causes lysosomal membrane rupture and the release of lysosomal contents into the cytoplasm (zhang2023lysosomalchloridetransporter pages 1-2). This membrane destabilization occurs because inadequate substrate digestion—resulting from reduced cathepsin activity in low-chloride conditions—leads to cargo accumulation and physical stress on the lysosomal membrane (zhang2023lysosomalchloridetransporter pages 1-2).
In osteoclasts, ClC-7 plays a specialized role in bone resorption by functioning at the ruffled border membrane facing the bone resorption lacuna (zifarelli2022theroleof pages 1-2, chen2026spectrumandfunctions pages 2-3). Together with the vacuolar H⁺-ATPase (V-ATPase), ClC-7 supports the acidification of the resorption lacuna to pH ~4.5, which is necessary for dissolving the hydroxyapatite mineral component of bone (chen2026spectrumandfunctions pages 2-3, rossler2021efficientgenerationof pages 1-5). The ClC-7-mediated chloride influx provides electrical shunting of the V-ATPase proton current, preventing the buildup of a lumen-positive voltage that would otherwise inhibit further acidification (bose2021neurodegenerationupondysfunction pages 2-4, chen2026spectrumandfunctions pages 2-3). Following mineral dissolution, acid proteases such as cathepsin K degrade the organic bone matrix (chen2026spectrumandfunctions pages 2-3).
ClC-7 dysfunction impairs autophagic flux and the degradation of autophagic cargo (bose2021neurodegenerationupondysfunction pages 1-2, rossler2021efficientgenerationof pages 1-5). Studies in ClC-7 knockout cells show increased autophagic flux despite unchanged lysosomal pH, suggesting that the chloride-dependent regulation of lysosomal proteases is critical for completing the degradative phase of autophagy (rossler2021efficientgenerationof pages 1-5). Loss of ClC-7 results in the accumulation of undegraded material within lysosomes, characteristic of lysosomal storage disease (zifarelli2022theroleof pages 1-2, bose2021neurodegenerationupondysfunction pages 1-2).
In professional phagocytes such as macrophages, ClC-7 is essential for efficient phagolysosome resolution and clearance of phagocytosed material (feng2023notjustprotons pages 1-2). Even when phagosomal acidification remains largely intact, ClC-7 knockout impairs the degradation of cargo and delays phagolysosome resolution, emphasizing the primacy of the chloride-dependent mechanism (feng2023notjustprotons pages 1-2). This function has important implications for innate immunity and the clearance of pathogens and cellular debris.
The molecular architecture of ClC-7 has been elucidated through high-resolution cryo-electron microscopy. Schrecker et al. (2020) reported structures of ClC-7 alone and in complex with OSTM1 at resolutions up to 2.8 Å (schrecker2020cryoemstructureof pages 1-2). These structures revealed the dimeric architecture of ClC-7, with each subunit containing an independent ion transport pathway in its transmembrane domain (schrecker2020cryoemstructureof pages 1-2). The structures captured ClC-7 in occluded states with chloride ions occupying binding sites in the permeation pathway (zifarelli2022theroleof pages 2-4).
A key structural feature is the phosphatidylinositol binding site at the interface between the transmembrane and cytoplasmic domains (zifarelli2022theroleof pages 2-4). The phosphate head group of PI3P (and by extension PI(3,5)P₂) interacts with residues from both domains, including the disease-associated residue Y715 (hilton2025mechanismofphosphoinositide pages 1-3). The structural studies also revealed a previously unrecognized role for the N-terminal domain, which interacts with both the transmembrane region and the CBS domains, forming an extensive intramolecular interaction network that may be unique to ClC-7 and ClC-6 among CLC proteins (zifarelli2022theroleof pages 2-4).
Biallelic loss-of-function mutations in CLCN7 cause approximately 10-15% of cases of autosomal recessive osteopetrosis (ARO), a severe bone disease characterized by defective osteoclast-mediated bone resorption (zifarelli2022theroleof pages 1-2, rossler2021efficientgenerationof pages 1-5). The resulting dense, brittle bones are prone to fractures despite their increased density (zifarelli2022theroleof pages 1-2). ARO is typically lethal during childhood without treatment, and patients often present with bone marrow failure, anemia, immune deficiency, osteomyelitis, and blindness due to optic nerve compression (rossler2021efficientgenerationof pages 1-5).
Importantly, CLCN7-related ARO is often accompanied by neurological manifestations including lysosomal storage disease in neurons and progressive neurodegeneration (zifarelli2022theroleof pages 1-2, bose2021neurodegenerationupondysfunction pages 1-2, bose2021neurodegenerationupondysfunction pages 2-4). Some patients exhibit brain malformations due to defective neuronal migration, and retinal degeneration has been observed in both patients and mouse models (bose2021neurodegenerationupondysfunction pages 1-2, rossler2021efficientgenerationof pages 1-5). This neuronopathic form of osteopetrosis distinguishes CLCN7-related disease from the more common form caused by mutations in TCIRG1 (encoding a V-ATPase subunit), which typically presents with osteopetrosis alone (rossler2021efficientgenerationof pages 1-5).
Heterozygous mutations in CLCN7 cause autosomal dominant osteopetrosis type II (ADO II), also known as Albers-Schönberg disease (zifarelli2022theroleof pages 1-2, polovitskaya2024gainoffunctionvariantsin pages 1-2). This is a more benign condition with incomplete penetrance and variable disease severity, even among relatives within the same family (zifarelli2022theroleof pages 1-2). ADO typically presents in adulthood and does not involve neurodegeneration (zifarelli2022theroleof pages 1-2). The dominant inheritance pattern may be explained by dominant-negative effects of mutant subunits on wild-type subunits in the ClC-7 dimer, or by deleterious gain-of-function effects (polovitskaya2024gainoffunctionvariantsin pages 1-2).
A remarkable recent discovery identified a novel allelic disorder caused by gain-of-function CLCN7 mutations (polovitskaya2024gainoffunctionvariantsin pages 1-2, polovitskaya2024gainoffunctionvariantsin pages 2-4). Polovitskaya et al. (2024) reported that de novo mutations p.Y715C and p.K285T cause a distinct syndrome characterized by hypopigmentation, organomegaly, delayed myelination and development (HOD syndrome) (polovitskaya2024gainoffunctionvariantsin pages 1-2, polovitskaya2024gainoffunctionvariantsin pages 2-4). Strikingly, patients with these mutations do not have osteopetrosis, the hallmark of classical CLCN7 disease (polovitskaya2024gainoffunctionvariantsin pages 1-2).
Electrophysiological analysis revealed that both mutations markedly increase ClC-7 ion transport activity (polovitskaya2024gainoffunctionvariantsin pages 1-2, polovitskaya2024gainoffunctionvariantsin pages 2-4). The mutations affect residues lining the PI(3,5)P₂ binding pocket and reduce the transporter's sensitivity to PI(3,5)P₂ inhibition (polovitskaya2024gainoffunctionvariantsin pages 1-2, polovitskaya2024gainoffunctionvariantsin pages 2-4). Both mutants also show a shift in voltage-dependent gating toward less positive potentials, predicting augmented pH gradient-driven chloride uptake into vesicles under physiological conditions (polovitskaya2024gainoffunctionvariantsin pages 1-2, polovitskaya2024gainoffunctionvariantsin pages 2-4). Overexpression of either mutant induces pathologically enlarged lysosome-related vacuoles in many tissues, a phenotype distinct from the lysosomal storage observed with loss of ClC-7 function (polovitskaya2024gainoffunctionvariantsin pages 1-2). The cellular effects of these gain-of-function mutations mimic those of PI(3,5)P₂ depletion, including enlarged, hyperacidified lysosomes (polovitskaya2024gainoffunctionvariantsin pages 1-2, hilton2025mechanismofphosphoinositide pages 1-3).
Mouse models with targeted deletion of Clcn7 or Ostm1 recapitulate the human disease phenotypes, displaying severe osteopetrosis, lysosomal storage disease in neurons and other tissues, neurodegeneration, and retinal degeneration (zifarelli2022theroleof pages 1-2, bose2021neurodegenerationupondysfunction pages 1-2, rossler2021efficientgenerationof pages 1-5). These models have been invaluable for understanding disease mechanisms and testing potential therapies.
The past three years have witnessed transformative advances in understanding ClC-7 function and disease mechanisms. Key developments include:
Chloride as a Direct Regulator of Lysosomal Function (Zhang et al., 2023; Wu et al., 2023): These studies fundamentally shifted the field's understanding by demonstrating that ClC-7-mediated chloride accumulation directly activates lysosomal cathepsins independent of pH effects, and is essential for lysosomal membrane integrity (zhang2023lysosomalchloridetransporter pages 1-2, feng2023notjustprotons pages 1-2).
Gain-of-Function Disease Mechanism (Polovitskaya et al., 2024): The identification of HOD syndrome established that both loss and gain of ClC-7 function can be pathogenic, with overactive transport causing a distinct disease phenotype without osteopetrosis (polovitskaya2024gainoffunctionvariantsin pages 1-2, polovitskaya2024gainoffunctionvariantsin pages 2-4).
Structural Basis of PI(3,5)P₂ Regulation (Hilton et al., 2025): This work provided unprecedented molecular detail on how lysosomal phosphoinositide signaling regulates ClC-7, revealing that PI(3,5)P₂ binding remodels the transporter structure by inducing close transmembrane-cytosolic domain association (hilton2025mechanismofphosphoinositide pages 1-3).
Comprehensive Integration in Osteoclast Biology (Chen et al., 2026): A recent comprehensive review synthesized the role of ClC-7 within the broader network of osteoclast ion channels and transporters, highlighting its importance as a disease mechanism and potential therapeutic target in bone disorders (chen2026spectrumandfunctions pages 2-3).
| Protein / entity | Gene symbol | UniProt ID | Primary function / transport mechanism | Substrates and stoichiometry | Main subcellular localization | Key regulatory / partner molecules | Associated diseases and inheritance | Key biological processes |
|---|---|---|---|---|---|---|---|---|
| H(+)/Cl(-) exchange transporter 7; ClC-7; chloride channel 7 alpha subunit | CLCN7 | P51798 | Electrogenic lysosomal Cl-/H+ antiporter of the CLC family; each subunit contains an independent transport pathway and the transporter shows slow voltage-dependent activation / strong outward rectification. In acidic compartments, ClC-7 uses the pH gradient to drive luminal chloride accumulation while exporting protons (zifarelli2022theroleof pages 1-2, zifarelli2022theroleof pages 2-4, schrecker2020cryoemstructureof pages 1-2, hilton2025mechanismofphosphoinositide pages 1-3) | 2 Cl- exchanged for 1 H+ in opposite directions; in lysosomes/resorption lacuna this is functionally described as uptake of 2 Cl- into the lumen coupled to 1 H+ efflux (bose2021neurodegenerationupondysfunction pages 1-2, polovitskaya2024gainoffunctionvariantsin pages 1-2, zifarelli2022theroleof pages 2-4, schrecker2020cryoemstructureof pages 1-2) | Predominantly lysosomal membrane in most cells; colocalizes with late endosome/lysosome markers; in osteoclasts additionally localizes to the ruffled border facing the resorption lacuna, where it supports extracellular acidification for bone resorption (zifarelli2022theroleof pages 1-2, bose2021neurodegenerationupondysfunction pages 2-4, schrecker2020cryoemstructureof pages 1-2) | OSTM1 is an obligatory beta-subunit required for stability, proper localization, and full function; OSTM1 forms a luminal protective cap over ClC-7. PI(3,5)P2 directly inhibits ClC-7; disease-causing gain-of-function variants such as Y715C and K285T reduce this inhibition. Structural/functional determinants include the gating glutamate E247, proton glutamate E314, ATP/CBS-domain interactions, and a phosphoinositide-binding interface linking transmembrane and cytosolic domains (zifarelli2022theroleof pages 1-2, polovitskaya2024gainoffunctionvariantsin pages 2-4, schrecker2020cryoemstructureof pages 1-2, hilton2025mechanismofphosphoinositide pages 1-3) | Autosomal recessive osteopetrosis (ARO) due to loss-of-function CLCN7 variants, often with lysosomal storage and possible neurodegeneration; autosomal dominant osteopetrosis (ADO II / Albers-Schönberg disease) due to heterozygous variants; gain-of-function CLCN7 disease / HOD syndrome with hypopigmentation, organomegaly, delayed myelination and development, and lysosomal storage without classic osteopetrosis; pathogenic CLCN7 dysfunction is also linked to neuronal lysosomal storage disease and retinal/neurologic phenotypes in model systems (zifarelli2022theroleof pages 1-2, polovitskaya2024gainoffunctionvariantsin pages 1-2, bose2021neurodegenerationupondysfunction pages 2-4, rossler2021efficientgenerationof pages 1-5) | Lysosomal ion homeostasis; accumulation of luminal chloride; support of lysosomal degradative function and cathepsin activation; maintenance of lysosomal membrane integrity; support of autophagic flux and cargo degradation; in osteoclasts, support of bone matrix dissolution/resorption by helping acidify the resorption lacuna together with V-ATPase (zhang2023lysosomalchloridetransporter pages 1-2, feng2023notjustprotons pages 1-2, rossler2021efficientgenerationof pages 1-5, schrecker2020cryoemstructureof pages 1-2) |
Table: This table summarizes the core molecular properties of human CLCN7/ClC-7, including transport mechanism, localization, regulation, disease associations, and biological roles. It is useful as a compact reference for functional annotation of the human lysosomal Cl-/H+ exchanger.
| Study | Key finding / discovery | Experimental approach | Significance |
|---|---|---|---|
| Zhang et al., 2023 | The ClC-7 ortholog maintains lysosomal luminal Cl- required for cathepsin B/L activity; loss of transporter function reduces chloride without abolishing acidification, causing defective cargo degradation and lysosomal membrane rupture. (zhang2023lysosomalchloridetransporter pages 1-2, feng2023notjustprotons pages 1-2) | C. elegans genetics; loss-of-function mutants of clh-6/ClC-7 ortholog; lysosomal membrane damage reporters; chloride and pH measurements; cathepsin activity assays; in vitro chloride supplementation experiments. (zhang2023lysosomalchloridetransporter pages 1-2, feng2023notjustprotons pages 1-2) | Shifted the field from viewing ClC-7 mainly as a support for acidification to recognizing luminal chloride itself as a direct regulator of lysosomal hydrolase function and membrane integrity. (zhang2023lysosomalchloridetransporter pages 1-2, feng2023notjustprotons pages 1-2) |
| Wu/Freeman et al., 2023 | ClC-7 establishes a roughly 2- to 4-fold luminal chloride gradient in lysosomes/phagolysosomes and is required for efficient degradation and phagolysosome resolution even when acidification remains largely intact. (feng2023notjustprotons pages 1-2) | Macrophage/phagolysosome functional studies summarized in JCB spotlight; ClC-7 knockout analysis; phagosomal degradation assays; chloride-sensitive measurements; assessment of phagolysosome maturation/resolution. (feng2023notjustprotons pages 1-2) | Strengthened evidence that ClC-7 has a primary chloride-homeostasis role in degradative organelles, with relevance to innate immunity and phagocytic clearance. (feng2023notjustprotons pages 1-2) |
| Polovitskaya et al., 2024 | Gain-of-function CLCN7 variants including Y715C and K285T cause HOD syndrome with hypopigmentation, organomegaly, delayed myelination/development, and lysosomal storage; the variants reduce PI(3,5)P2-mediated inhibition and shift voltage dependence to favor excess transport. (polovitskaya2024gainoffunctionvariantsin pages 1-2, polovitskaya2024gainoffunctionvariantsin pages 2-4) | Human genetics in affected patients; targeted sequencing; whole-cell patch clamp of plasma-membrane-targeted human ClC-7 mutants; lysosomal morphology studies in overexpression systems and patient fibroblasts. (polovitskaya2024gainoffunctionvariantsin pages 1-2, polovitskaya2024gainoffunctionvariantsin pages 2-4) | Demonstrated that not only loss-of-function but also transporter overactivity is pathogenic, defining a distinct CLCN7 disease mechanism separate from classical osteopetrosis. (polovitskaya2024gainoffunctionvariantsin pages 1-2, polovitskaya2024gainoffunctionvariantsin pages 2-4) |
| Hilton et al., 2025 | PI(3,5)P2 directly inhibits ClC-7 by binding at the transmembrane-cytosolic interface and remodeling transporter structure; disease-causing mutations disrupt this inhibitory network and increase transport activity. (hilton2025mechanismofphosphoinositide pages 1-3) | Functional electrophysiology, cryo-EM structural analysis, and molecular dynamics/computational modeling of ClC-7/Ostm1 and interface mutants. (hilton2025mechanismofphosphoinositide pages 1-3) | Provided a structural mechanism linking lysosomal phosphoinositide signaling to ClC-7 slow gating, lysosomal pH regulation, and gain-of-function disease. (hilton2025mechanismofphosphoinositide pages 1-3) |
| Chen et al., 2026 | Review synthesis identifies ClC-7 as one of the best-established ion transport systems in osteoclasts, acting with V-ATPase at the ruffled border and lysosomal system to support bone resorption and osteoclast function. (chen2026spectrumandfunctions pages 2-3) | Narrative review integrating osteoclast ion-channel/transporter literature, localization data, substrate/function assignments, and disease links. (chen2026spectrumandfunctions pages 2-3) | Useful translational summary placing CLCN7 in the broader osteoclast ion-transport network and highlighting its importance as a disease mechanism and potential therapeutic target in bone disorders. (chen2026spectrumandfunctions pages 2-3) |
Table: This table summarizes major CLCN7/ClC-7 advances from 2023-2025, emphasizing new mechanistic insights into lysosomal chloride homeostasis, disease-causing gain-of-function variants, and structural regulation by PI(3,5)P2. It is useful for quickly linking each study to its methods and biological significance.
Multiple experimental approaches have established the functional properties of ClC-7:
Patch-clamp electrophysiology of plasma membrane-targeted ClC-7 has demonstrated the 2Cl⁻/H⁺ exchange stoichiometry, voltage-dependent gating, and strong outward rectification (polovitskaya2024gainoffunctionvariantsin pages 1-2, zifarelli2022theroleof pages 2-4, polovitskaya2024gainoffunctionvariantsin pages 2-4).
Cryo-EM structural analysis at 2.8 Å resolution has revealed the architecture of the ClC-7/OSTM1 complex, ion binding sites, transport pathway, and regulatory lipid binding sites (schrecker2020cryoemstructureof pages 1-2, hilton2025mechanismofphosphoinositide pages 1-3).
Functional studies in native lysosomes using chloride-sensitive probes have measured the 2-4 fold chloride gradient established by ClC-7 (zhang2023lysosomalchloridetransporter pages 1-2, feng2023notjustprotons pages 1-2).
In vitro enzyme assays with purified cathepsins have demonstrated direct chloride-dependent activation of lysosomal proteases (zhang2023lysosomalchloridetransporter pages 1-2).
Human iPSC-derived osteoclasts from ARO patients with CLCN7 mutations show complete loss of bone resorption capacity, validating the critical role of ClC-7 in osteoclast function (rossler2021efficientgenerationof pages 1-5).
Mouse genetic models (Clcn7⁻/⁻ and Ostm1⁻/⁻) recapitulate human disease phenotypes including osteopetrosis, neurodegeneration, lysosomal storage, and retinal degeneration (zifarelli2022theroleof pages 1-2, bose2021neurodegenerationupondysfunction pages 1-2).
C. elegans genetic studies have provided tractable systems for dissecting ClC-7 function in lysosomal membrane integrity and cathepsin activation (zhang2023lysosomalchloridetransporter pages 1-2).
The CLCN7 gene encodes ClC-7, a lysosomal 2Cl⁻/H⁺ antiporter that plays essential roles in lysosomal ion homeostasis, bone resorption, and cellular degradation. The primary function of ClC-7 is to accumulate chloride in the lysosomal lumen through electrogenic exchange with protons. This chloride accumulation serves dual purposes: it provides electrical shunting to support V-ATPase-mediated acidification, and it directly activates lysosomal cathepsins and other hydrolases independent of pH. ClC-7 requires its β-subunit OSTM1 for proper function and is negatively regulated by the lysosomal lipid PI(3,5)P₂.
ClC-7 localizes to lysosomes in all cells and additionally to the osteoclast ruffled border, where it acidifies the bone resorption lacuna. Dysfunction of ClC-7 causes a spectrum of human diseases including osteopetrosis, lysosomal storage disease, and neurodegeneration, with both loss-of-function and gain-of-function mutations being pathogenic. Recent structural and functional studies have provided unprecedented molecular insight into ClC-7's transport mechanism, regulatory mechanisms, and disease pathogenesis, establishing this transporter as a critical regulator of lysosomal function with broad implications for bone biology, neurodegenerative disease, and cellular metabolism.
References
(zifarelli2022theroleof pages 1-2): Giovanni Zifarelli. The role of the lysosomal cl−/h+ antiporter clc-7 in osteopetrosis and neurodegeneration. Cells, 11:366, Jan 2022. URL: https://doi.org/10.3390/cells11030366, doi:10.3390/cells11030366. This article has 23 citations.
(bose2021neurodegenerationupondysfunction pages 1-2): Shroddha Bose, Hailan He, and Tobias Stauber. Neurodegeneration upon dysfunction of endosomal/lysosomal clc chloride transporters. Frontiers in Cell and Developmental Biology, Feb 2021. URL: https://doi.org/10.3389/fcell.2021.639231, doi:10.3389/fcell.2021.639231. This article has 45 citations.
(zifarelli2022theroleof pages 2-4): Giovanni Zifarelli. The role of the lysosomal cl−/h+ antiporter clc-7 in osteopetrosis and neurodegeneration. Cells, 11:366, Jan 2022. URL: https://doi.org/10.3390/cells11030366, doi:10.3390/cells11030366. This article has 23 citations.
(schrecker2020cryoemstructureof pages 1-2): Marina Schrecker, Julia Korobenko, and Richard K Hite. Cryo-em structure of the lysosomal chloride-proton exchanger clc-7 in complex with ostm1. eLife, Aug 2020. URL: https://doi.org/10.7554/elife.59555, doi:10.7554/elife.59555. This article has 77 citations and is from a domain leading peer-reviewed journal.
(polovitskaya2024gainoffunctionvariantsin pages 1-2): Maya M. Polovitskaya, Tanushka Rana, Kurt Ullrich, Simona Murko, Tatjana Bierhals, Guido Vogt, Tobias Stauber, Christian Kubisch, René Santer, and Thomas J. Jentsch. Gain-of-function variants in clcn7 cause hypopigmentation and lysosomal storage disease. Journal of Biological Chemistry, 300:107437, Jul 2024. URL: https://doi.org/10.1016/j.jbc.2024.107437, doi:10.1016/j.jbc.2024.107437. This article has 17 citations and is from a domain leading peer-reviewed journal.
(polovitskaya2024gainoffunctionvariantsin pages 2-4): Maya M. Polovitskaya, Tanushka Rana, Kurt Ullrich, Simona Murko, Tatjana Bierhals, Guido Vogt, Tobias Stauber, Christian Kubisch, René Santer, and Thomas J. Jentsch. Gain-of-function variants in clcn7 cause hypopigmentation and lysosomal storage disease. Journal of Biological Chemistry, 300:107437, Jul 2024. URL: https://doi.org/10.1016/j.jbc.2024.107437, doi:10.1016/j.jbc.2024.107437. This article has 17 citations and is from a domain leading peer-reviewed journal.
(hilton2025mechanismofphosphoinositide pages 1-3): Jacob K. Hilton, Yifei Lin, Eric Sefah, Justin C. Deme, Joanne L. Parker, Matthew J. Langton, Michael Grabe, Susan Lea, Simon Newstead, and Joseph A. Mindell. Mechanism of phosphoinositide regulation of lysosomal ph via inhibition of clc-7. BioRxiv, Oct 2025. URL: https://doi.org/10.1101/2025.10.01.679551, doi:10.1101/2025.10.01.679551. This article has 0 citations.
(bose2021neurodegenerationupondysfunction pages 2-4): Shroddha Bose, Hailan He, and Tobias Stauber. Neurodegeneration upon dysfunction of endosomal/lysosomal clc chloride transporters. Frontiers in Cell and Developmental Biology, Feb 2021. URL: https://doi.org/10.3389/fcell.2021.639231, doi:10.3389/fcell.2021.639231. This article has 45 citations.
(chen2026spectrumandfunctions pages 2-3): Hongyu Chen, Yanli Zhang, Yulong Zhu, Xiang Xiao, Shanshan Huang, and Xiaohong Duan. Spectrum and functions of ion channels and transporters in osteoclasts. Bone Research, Mar 2026. URL: https://doi.org/10.1038/s41413-026-00513-9, doi:10.1038/s41413-026-00513-9. This article has 1 citations and is from a domain leading peer-reviewed journal.
(rossler2021efficientgenerationof pages 1-5): Uta Rössler, Anna Floriane Hennig, Nina Stelzer, Shroddha Bose, Johannes Kopp, Kent Søe, Lukas Cyganek, Giovanni Zifarelli, Salaheddine Ali, Maja Von Der Hagen, Elisabeth Tamara Strässler, Gabriele Hahn, Michael Pusch, Tobias Stauber, Zsuzsanna Izsvák, Manfred Gossen, Harald Stachelscheid, and Uwe Kornak. Efficient generation of osteoclasts from human induced pluripotent stem cells and functional investigations of lethal clcn7‐related osteopetrosis. Journal of Bone and Mineral Research, Apr 2021. URL: https://doi.org/10.1002/jbmr.4322, doi:10.1002/jbmr.4322. This article has 57 citations and is from a highest quality peer-reviewed journal.
(zhang2023lysosomalchloridetransporter pages 1-2): Qianqian Zhang, Yuan-gao Li, Y. Jian, Meijiao Li, and Xiaochen Wang. Lysosomal chloride transporter clh-6 protects lysosome membrane integrity via cathepsin activation. The Journal of Cell Biology, Apr 2023. URL: https://doi.org/10.1083/jcb.202210063, doi:10.1083/jcb.202210063. This article has 28 citations.
(feng2023notjustprotons pages 1-2): Xinghua Feng, Siyu Liu, and Haoxing Xu. Not just protons: chloride also activates lysosomal acidic hydrolases. The Journal of Cell Biology, May 2023. URL: https://doi.org/10.1083/jcb.202305007, doi:10.1083/jcb.202305007. This article has 18 citations.